From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA grants nivolumab breakthrough designation for advanced bladder cancer

from OncLive

The FDA has granted nivolumab (Opdivo) a breakthrough therapy designation for the treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) after the failure of a platinum-containing regimen, according to Bristol-Myers Squibb, the manufacturer of the PD-1 inhibitor. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063